Dual Therapy for Myopia Control - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Dual Therapy for Myopia Control

Randomized trial shows combining atropine with DIMS lenses significantly reduces axial elongation in children

  • June 4, 2026

  • 4 min

Share

Clinical Scorecard: Dual Therapy for Myopia Control

At a Glance

CategoryDetail
Condition
Key MechanismsCombination of low-dose atropine and Defocus Incorporated Multiple Segments (DIMS) spectacle lenses.
Target Population
Care Setting

Key Highlights

  • Combination therapy showed a statistically significant reduction in axial elongation compared to atropine alone.
  • 40% of children receiving combination therapy exhibited no axial elongation over 12 months.
  • Both atropine and DIMS lenses are established monotherapies, each reducing myopia progression by approximately 50–60%.

Guideline-Based Recommendations

Diagnosis

    Management

    • Consider combination therapy of low-dose atropine and DIMS lenses for myopia control, as supported by the ASPECT trial.

    Monitoring & Follow-up

      Risks

        Patient & Prescribing Data

        Combination therapy may enhance control of axial elongation.

        Clinical Best Practices

          Related Resources & Content

          Original Source(s)

          Dual Therapy for Myopia Control

          • June 4, 2026

          Related Content

          Educators weigh how to use AI without losing critical thinking

          Greater productivity is not necessarily indicative of greater knowledge.

          Dead bag syndrome may present asymmetrically

          Spontaneous posterior capsular rupture affected both eyes years following uncomplicated cataract surgery, but intraocular lens dislocation required surgery in only 1 eye.

          Earlier Intervention for Neurotrophic Keratitis?

          New data support earlier use of decellularized basement membrane grafts in neurotrophic keratitis

          • September 8, 2026

          • 2 min